Point of Care Diagnostics Market Size and Forecast 2025–2033

The global Point of Care (POC) Diagnostics Market is entering a transformative decade—one driven by urgent healthcare needs, rapid technological evolution, and an unprecedented demand for fast, reliable, and decentralized testing. According to Renub Research, the POC diagnostics market will reach US$ 105.22 billion by 2033, rising from US$ 50.08 billion in 2024, with a CAGR of 8.60% between 2025 and 2033.

This explosive growth underscores a fundamental shift in how the world approaches disease detection and patient management. With infectious diseases on the rise, chronic illnesses becoming more prevalent, and consumer expectations rising for instant medical information, POC testing is no longer a supplementary tool—it is becoming a healthcare necessity.

Understanding the Point of Care Diagnostics Landscape

Point-of-care diagnostics refers to medical tests conducted near or at the site of patient care, eliminating the need to send samples to central laboratories. POC devices provide real-time, actionable results—often within minutes.

These tools are increasingly used across hospitals, clinics, retail pharmacies, emergency departments, and even homes. From monitoring blood glucose to detecting infectious diseases, POC technologies reduce treatment delays and enable faster clinical decisions.

POC tests are vital in:

Primary care centers for glucose, cholesterol, infectious diseases

Emergency rooms for cardiac markers and blood gas analysis

Homes for pregnancy and ovulation testing

Rural areas with limited laboratory infrastructure

With lab-on-a-chip innovation, miniaturized biosensors, and AI-enabled platforms, POC testing is becoming more accurate, more affordable, and more essential than ever.

Market Outlook: Key Figures (Renub Research)

Report Features Details

Base Year 2024

Forecast Years 2025–2033

Historical Years 2020–2024

Market Size 2024 US$ 50.08 Billion

Market Size 2033 US$ 105.22 Billion

CAGR 2025–2033 8.60%

This sustained high growth reflects powerful underlying catalysts—ranging from the rise of chronic diseases to increasing public awareness about preventive care.

What’s Driving the Surging Global Demand?

1. Technological Advancements and Miniaturization

The biggest booster for the POC diagnostics market is innovation.

Breakthroughs in:

lab-on-a-chip systems

AI-powered diagnostics

portable screening devices

networked biosensors

are enabling extremely accurate real-time testing.

Companies are investing heavily in compact, multipurpose devices capable of running multiple tests simultaneously. Collaborations like the Molbio Diagnostics–SigTuple partnership (2023) illustrate how AI and miniaturization are blending to build next-generation diagnostic solutions.

These advancements reduce test turnaround time, expand testing capabilities, and enhance usability across professional and home settings.

2. Growing Emphasis on Personalized Medicine

Healthcare is moving away from one-size-fits-all treatment.

National health agencies, including the National Cancer Institute (NCI), are launching precision medicine initiatives to tailor therapies to individual patient needs. POC diagnostics is central to this revolution, enabling:

real-time biomarker detection

rapid therapy response monitoring

patient-specific disease tracking

As precision medicine gains global momentum, POC platforms will become indispensable diagnostic tools.

3. Rising Burden of Chronic and Infectious Diseases

According to WHO, non-communicable diseases (NCDs) cause 41 million deaths annually, accounting for 74% of global deaths.

Chronic conditions like:

diabetes

cardiovascular disorders

respiratory diseases

require continuous monitoring—making POC kits crucial for disease management.

In addition:

The high prevalence of HIV, COVID-19, flu, and other infectious diseases

Growing antimicrobial resistance

Increased travel and urbanization

have accelerated demand for quick, decentralized diagnostic tools.

POC tests offer fast identification, essential for early intervention and outbreak prevention—particularly in remote or underserved areas.

Challenges Facing the POC Diagnostics Market

1. Accuracy Limitations

While POC tests offer speed, accuracy remains a concern for some devices. Factors like user error, environmental conditions, and lower sensitivity (compared to central labs) restrain adoption in certain regions.

High device costs add another barrier, especially in developing countries.

2. Regulatory Barriers and Quality Control Issues

In low-resource settings, ensuring adherence to regulatory standards is extremely challenging.

Common issues include:

lack of trained personnel

inconsistent quality assurance

poor infrastructure

limited calibration systems

These challenges may result in inaccurate results, reducing healthcare provider confidence and slowing market penetration.

Segment-Level Analysis: What’s Leading the Market?

✔ Glucose Monitoring Kits – Dominating Product Segment

Glucose monitoring kits are the backbone of the POC diagnostics market.

Why they lead:

Global diabetes epidemic (38.4 million Americans affected—CDC 2021)

High adoption of self-monitoring devices

Easy availability via OTC channels

Critical importance in daily diabetes management

Their widespread use among hospitals, home-care patients, and self-management users ensures robust and stable market dominance.

✔ Lateral Flow Technology – Leading the Technology Segment

Lateral flow assays (LFAs) are the most widely used POC technology due to:

low cost

simple design

rapid results

suitability for home and decentralized testing

From pregnancy tests to COVID-19 kits, lateral flow systems remain the gold standard for mass diagnostic deployment.

✔ Over-the-Counter (OTC) Devices – Fastest Growing Point-of-Prescription Segment

OTC devices are revolutionizing diagnostic accessibility.

Consumers increasingly rely on at-home screening for:

pregnancy

fertility

infectious diseases

chronic conditions

Rising health awareness and preventive care trends have positioned OTC diagnostic kits as one of the most transformative market segments.

✔ Professional Diagnostic Centers – Leading End-User Segment

These centers remain key to global POC diagnostics adoption due to:

advanced diagnostic infrastructures

skilled technologists

access to multi-parameter equipment

demand for rapid turnaround tests

Their credibility and diagnostic accuracy keep them as the primary professional testing hub.

Regional Market Outlook

United States – The Global Leader

The US dominates the global POC diagnostics landscape due to:

high chronic disease prevalence

adoption of advanced home-testing technologies

strong regulatory approvals

robust healthcare expenditure

The 2022 FDA approval of NOWDiagnostic’s ADEXUSDx hCG test further highlights the country’s leadership in innovation and implementation.

Germany – A Technological Powerhouse

Germany benefits from:

a strong aging population

advanced medical infrastructure

rising preference for rapid diagnostic solutions

Widespread adoption of OTC and home-based test kits continues to drive growth.

India – One of the Fastest Growing Markets

India’s market surge is driven by:

high rural population

expanding healthcare access

government health initiatives

prevalence of diabetes and infectious diseases

The launch of Cipla’s Cippoint POC system (2023) reflects growing domestic innovation.

Saudi Arabia – Powered by Healthcare Modernization

Saudi Arabia’s Vision 2030 is pushing major investments in diagnostic expansion. Rising chronic disease cases and increasing healthcare digitization support long-term growth of the POC testing market.

Market Segmentation Snapshot

Products (9 Segments)

Glucose Monitoring Kits, Infectious Disease Kits, Pregnancy & Fertility Kits, Hematology Kits, Cardiometabolic Kits, Urinalysis Kits, Cholesterol Strips, Drug Abuse Kits, Others.

Technology (6 Segments)

Lateral Flow, Agitation, Flow Through, Solid Phase, Biosensor, Others.

Point of Prescription (2 Segments)

Prescription Devices, OTC Devices.

End-Users (4 Segments)

Diagnostic Centers, Research Labs, Home Care, Others.

Countries Covered: 25

Including US, Canada, France, Germany, UK, China, India, Japan, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa, and more.

Key Companies

Sysmex, Abbott, BD, Danaher, Quidel, Roche, Thermo Fisher, Bio-Rad.

Final Thoughts

Point-of-care diagnostics is not just a market—it is a medical revolution. As healthcare shifts toward decentralization, immediacy, and patient empowerment, POC testing will be at the forefront of global diagnostics.

By 2033, with the market projected to exceed US$ 105 billion, the world will witness POC technologies reshaping how patients interact with healthcare—making diagnostics faster, smarter, more accessible, and more personalized than ever before.